Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott has received the US Food and Drug Administration's (FDA) approval for AndroGel (testosterone gel) 1.62%, a low-volume formulation to help restore low testosterone levels in men.
Subscribe to our email newsletter
AndroGel (testosterone gel) 1.62% is a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%.
At the starting dose, the new AndroGel 1.62% contains 40.5mg of testosterone in two pump presses, whereas AndroGel 1% contains 50mg of testosterone in four pump presses.
The company expects to launch AndroGel 1.62% in the second quarter of 2011.
Abbott Metabolics divisional vice president Jim Hynd said AndroGel 1% has been trusted by patients and physicians for more than a decade.
"With the approval of AndroGel 1.62%, Abbott now offers another innovation in testosterone delivery for men with hypogonadism to treat their condition," Hynd said.